SPONSORSHIP

iMig 2018 wishes to warmly thank the following organizations for their generous support of the Conference:

GOLD SPONSOR

KAZAN, McClain
Satterley & Greenwood
A PROFESSIONAL LAW CORPORATION
Helping Asbestos Victims Since 1974
KAZANLAW.COM

SILVER SPONSOR

BAYER

BRONZE SPONSORS

SUPPORTERS

iMig 2018 would like to thank the following organizations for their support of the Conference.

• Area Endowment Fund, held at Vancouver Foundation
• Canadian Union of Public Employees (CUPE)
• Cement Finishing Labour Relations Association
• Manitoba Building Trades
• Pinnacle Biologics

GENERAL SUPPORT
# TABLE OF CONTENTS

## Scientific Information
- Welcome Message .................................................. 3
- Committees .......................................................... 4
- Scientific Program
  - Program at a Glance ........................................... 5-6
  - Thursday, May 3 ............................................. 7-11
  - Friday, May 4 ................................................ 12-17
  - Saturday, May 5 ............................................... 18-20
- Poster Listings ..................................................... 21-25
- Information for Invited Speakers and Abstract Presenters .......... 26

## Conference Information
- Conference Venue .................................................. 29
- General Information from A to Z ................................ 31-32
- Awards
  - Wagner Medal .................................................. 34
  - iMig Awards .................................................... 34
  - Best Investigator Award ..................................... 34
  - Young Investigator Awards .................................. 34
  - Developing Nations Travel Grants ........................... 34
- Industry Supported Symposia .................................... 35

## Exhibition Information
- Exhibition Location and Hours ................................ 36
- Exhibition Highlights ............................................ 36
- Exhibition Floor Plan ............................................. 36
- Exhibitor Listing .................................................. 36
- Exhibition Biographies ............................................ 37-38
On behalf of the local organizing committee, we would like to extend an invitation to join us for the 14th meeting of the International Mesothelioma Interest Group (iMig 2018) to be held in Ottawa, Canada in May 2018. Our multidisciplinary meeting will bring together over 500 delegates from around the world, and feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. The meeting will offer plenty of networking opportunities with leading scientists and researchers, friends and colleagues.

We are very proud and excited to be hosting iMig for the first time in Canada in our nation’s capital. Springtime in Ottawa is beautiful, and offers a variety of cultural and family-friendly activities for you to enjoy.

We look forward to hosting you at iMig 2018.
The International Mesothelioma Interest Group (iMig) is an independent international group of scientists and clinicians working to understand, cure and prevent Mesothelioma. We invite you to become a member of iMig to strengthen our international voice and to improve the scientific exchange and knowledge about this malignancy.

Why Join iMig?
Membership is about communication and participation. Members will have access to all features of the iMig website (iMig.org) and opportunities to contribute content there. Via email, members will receive notices of updates to the website such as those involving upcoming meetings, funding or career opportunities, new presentations and research breakthroughs. Although no membership dues are requested at this time, members are asked to participate in iMig by contributing to the website and/or participating in the biannual international meetings.

Finally, members help iMig by being part of our international community and showing their interest in understanding and ultimately preventing and defeating Mesothelioma.

iMig Officers 2016 - 2018
President:
Sam Armato, PhD, Chicago, USA
Secretary:
Jeremy Steele, MD, MRCP, London, United Kingdom
Treasurer:
Paul Baas, MD, PhD, Amsterdam, The Netherlands

iMig Board Members 2016 - 2018
Steve Albleda, MD, Philadelphia, USA
Samuel Armato, PhD, Chicago, USA
Paul Baas, MD, PhD, Amsterdam, The Netherlands
Courtney Broadus, MD, San Francisco, USA
Dean Fennel, MD, PhD, Leicester, United Kingdom
Rabab Gafaar, MD, Cairo, Egypt
Marie-Claude Jaurand, PhD, Paris, France
Hedy Lee Kindler, MD, Chicago, USA
Sakari Knutsila, MD, Helsinki, Finland
Steven Mutsaers, MD, PhD, Perth, Australia
Luciano Mutti, MD, PhD, Salford, UK
Takashi Nakano, MD, PhD, Hyogo, Japan
Harvey Pass, MD, New York, USA
Bruce Robinson, MD, Perth, Australia
Arnaud Scherpereel, MD, PhD, Lille, France
Jeremy Steele, MD, London, United Kingdom
Daniel Sterman, MD, Philadelphia, USA
Jim teWaterNaude, MBChb, Cape Town, South Africa
Walter Weder, MD, Zurich, Switzerland

iMig 2018 Meeting
Oversight Committee
Samuel Armato, PhD, Chicago, USA
Dean Fennell, PhD, MRCP, Leicester, United Kingdom
Hedy Lee Kindler, MD, Chicago, USA
Scott Laurie, MD, Ottawa, Canada
Donna Maziak, MD FRCSC, Ottawa, Canada
Luciano Mutti, MD, PhD, Salford, UK
Arnaud Scherpereel, MD, PhD, Lille, France
Walter Weder, MD, Zurich, Switzerland
## PROGRAM AT A GLANCE

### Wednesday, May 2, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Welcome Networking Reception 18:30 - 21:30</td>
</tr>
<tr>
<td>08:00</td>
<td>Opening Address 8:30 - 8:45</td>
</tr>
<tr>
<td>08:30</td>
<td>Plenary I 8:45 - 10:15</td>
</tr>
<tr>
<td>09:00</td>
<td>Poster Viewing with Coffee 10:15 - 11:00</td>
</tr>
<tr>
<td>09:30</td>
<td>Parallel mini-symposia x 3 11:00 - 12:30</td>
</tr>
<tr>
<td>10:00</td>
<td>Lunch Break in Exhibit Hall 12:30 - 13:45</td>
</tr>
<tr>
<td>10:30</td>
<td>Industry Symposium 12:45 - 13:45</td>
</tr>
<tr>
<td>11:00</td>
<td>Parallel mini-symposia x 3 13:45 - 15:15</td>
</tr>
<tr>
<td>11:30</td>
<td>Plenary II 16:00 - 17:30</td>
</tr>
<tr>
<td>12:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>12:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break 12:00 - 13:00</td>
</tr>
<tr>
<td>13:30</td>
<td>Plenary II 16:00 - 17:30</td>
</tr>
<tr>
<td>14:00</td>
<td>Parallel mini-symposia x 3 13:45 - 15:15</td>
</tr>
<tr>
<td>14:30</td>
<td>Plenary III 18:00 - 19:30</td>
</tr>
<tr>
<td>15:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>15:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>16:00</td>
<td>Lunch Break 12:00 - 13:00</td>
</tr>
<tr>
<td>16:30</td>
<td>Plenary III 18:00 - 19:30</td>
</tr>
<tr>
<td>17:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>18:00</td>
<td>Lunch Break 12:00 - 13:00</td>
</tr>
<tr>
<td>18:30</td>
<td>Plenary III 18:00 - 19:30</td>
</tr>
<tr>
<td>19:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>19:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>20:00</td>
<td>Welcome Networking Reception 18:30 - 21:30</td>
</tr>
<tr>
<td>20:30</td>
<td>Opening Address 8:30 - 8:45</td>
</tr>
<tr>
<td>21:00</td>
<td>Plenary I 8:45 - 10:15</td>
</tr>
<tr>
<td>21:30</td>
<td>Poster Viewing with Coffee 10:15 - 11:00</td>
</tr>
</tbody>
</table>

### Thursday, May 3, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Welcome Networking Reception 18:30 - 21:30</td>
</tr>
<tr>
<td>08:00</td>
<td>Opening Address 8:30 - 8:45</td>
</tr>
<tr>
<td>08:30</td>
<td>Plenary I 8:45 - 10:15</td>
</tr>
<tr>
<td>09:00</td>
<td>Poster Viewing with Coffee 10:15 - 11:00</td>
</tr>
<tr>
<td>09:30</td>
<td>Parallel mini-symposia x 3 11:00 - 12:30</td>
</tr>
<tr>
<td>10:00</td>
<td>Lunch Break in Exhibit Hall 12:30 - 13:45</td>
</tr>
<tr>
<td>10:30</td>
<td>Industry Symposium 12:45 - 13:45</td>
</tr>
<tr>
<td>11:00</td>
<td>Parallel mini-symposia x 3 13:45 - 15:15</td>
</tr>
<tr>
<td>11:30</td>
<td>Plenary II 16:00 - 17:30</td>
</tr>
<tr>
<td>12:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>12:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>13:00</td>
<td>Lunch Break 12:00 - 13:00</td>
</tr>
<tr>
<td>13:30</td>
<td>Plenary II 16:00 - 17:30</td>
</tr>
<tr>
<td>14:00</td>
<td>Parallel mini-symposia x 3 13:45 - 15:15</td>
</tr>
<tr>
<td>14:30</td>
<td>Plenary III 18:00 - 19:30</td>
</tr>
<tr>
<td>15:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>15:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>16:00</td>
<td>Lunch Break 12:00 - 13:00</td>
</tr>
<tr>
<td>16:30</td>
<td>Plenary III 18:00 - 19:30</td>
</tr>
<tr>
<td>17:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
<tr>
<td>18:00</td>
<td>Lunch Break 12:00 - 13:00</td>
</tr>
<tr>
<td>18:30</td>
<td>Plenary III 18:00 - 19:30</td>
</tr>
<tr>
<td>19:00</td>
<td>Poster Viewing with Coffee 15:15 - 16:00</td>
</tr>
<tr>
<td>19:30</td>
<td>Poster Mixer with Poster Discussions 17:30 - 18:30</td>
</tr>
</tbody>
</table>
### SCIENTIFIC PROGRAM

**Thursday, May 3, 2018**

#### 08:30 - 08:45
**Opening Address**  
Room: Confederation I – Level 4

#### 08:45 - 10:15
**PL01: Plenary Session 01 - Global Perspective on Trends in Mesothelioma**  
Track: Epidemiology  
Chairs: Jim teWaterNaude, South Africa & Donna Maziak, Canada  
Room: Confederation I – Level 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td><strong>PL01.01: Nordic Perspective</strong></td>
<td>Gunnar Hillerdal, Karolinska Hospital</td>
<td>Sweden</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>PL01.02: North American Perspective</strong></td>
<td>Paul Demers, Cancer Care Ontario</td>
<td>Canada</td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td><strong>PL01.03: Oceanian Perspective</strong></td>
<td>Matthew Soeberg, The University of Sydney</td>
<td>Australia</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td><strong>PL01.04: Peripheral Blood DNA Methylation as Potential Biomarker for Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects</strong></td>
<td>Giuseppe Matullo, Italian Institute for Genomic Medicine and Department of Medical Sciences</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td><strong>PL01.05: Malignant Pleural Mesothelioma (MPM): A Surveillance, Epidemiology and End Results (SEER) Database Analysis</strong></td>
<td>Hala Aziz, National Cancer Institute</td>
<td>Egypt</td>
<td></td>
</tr>
<tr>
<td>09:50</td>
<td><strong>PL01.06: Asbestos Disease Research in Former Soviet Union and Russia: Literature Comparisons with United Kingdom and Japan</strong></td>
<td>Oluf Røe, Norwegian University of Science and Technology</td>
<td>Norway</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td><strong>PL01.07: Childhood School Attendance Near an Asbestos Cement Plant and Adult Mesothelioma Risk</strong></td>
<td>Sofie Dalsgaard, Aalborg University</td>
<td>Denmark</td>
<td></td>
</tr>
<tr>
<td>10:10</td>
<td><strong>PL01.08: Question &amp; Answer Period</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 10:15 - 11:00
**Poster Viewing with Coffee**  
Room: Confederation II/III - Level 4

#### 11:00 - 12:30
**MS01: Mini Symposium 01 - Patterns of Practice, a Global Perspective**  
Track: Nursing  
Chairs: Rayelle Richard, Canada & Melissa Culligan, United States  
Room: Confederation I – Level 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>MS01.01: North American Perspective: Highlighting the Role of the Mesothelioma Nurse in a Multidisciplinary Clinic</strong></td>
<td>Anastasia Bykova, University Health Network</td>
<td>Canada</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td><strong>MS01.02: UK Perspective: Lessons from the UK</strong></td>
<td>Liz Darlison, Mesothelioma UK</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td><strong>MS01.03: A South African Perspective</strong></td>
<td>Phemelo Magabanyane, Asbestos Relief Trust</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td><strong>MS01.04: A Nurse's Expertise in the Conduct of Clinical Trials in Mesothelioma</strong></td>
<td>Buerkley Rose, University of Chicago</td>
<td>United States</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>MS01.05: Case-Based Discussion</strong> (Surgical / Non Surgical)</td>
<td>Melissa Culligan, University of Maryland School of Medicine</td>
<td>United States</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td><strong>MS01.06: Question &amp; Answer Period</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11:00 - 12:30  
**MS02: Mini Symposium 02 - Molecular Pathways and Diagnosis in MPM**  
Track: Pathology  
Chairs: Aliya Husain, United States & Andrew Churg, Canada  
Room: Provinces I – Level 4

11:00  
**MS02.01: Grading of Mesothelioma**  
Aliya Husain, University of Chicago, United States

11:15  
**MS02.02: Live Cell Imaging for the Diagnosis of Malignant Pleural Mesothelioma by Needle-Based Confocal Laser Endomicroscopy (nCLE)**  
Paul Baas, Netherlands Cancer Institute, Netherlands  
(Abstract ID: 832)

11:25  
**MS02.03: MET Amplification Status and Expression in Malignant Mesothelioma**  
Eric Santoni-Rugiu, Rigshospitalet, Denmark  
(Abstract ID: 788)

11:35  
**MS02.04: The Role of EZH2 in the Proliferation, Migration, and Tumorigenicity of Malignant Mesothelioma**  
Tohru Tsujimura, Hyogo College of Medicine, Japan  
(Abstract ID: 679)

11:45  
**MS02.05: HEG1 is a New Immunohistochemical Marker for the Pathological Diagnosis of Malignant Mesothelioma**  
Kenzo Hiroshima, Tokyo Women's Medical University, Japan  
(Abstract ID: 623)

11:55  
**MS02.06: Molecular Pathways and Biomarkers in Diagnosis and Prognosis of MPM**  
Sanja Dacic, Pittsburg University Hospital, United States

12:10  
**MS02.07: Molecular Subtypes Characterization of Malignant Pleural Mesothelioma and Deconvolution Approach for Prognostic Assessment**  
Yuna Blum, Ligue Nationale Contre Le Cancer, France  
(Abstract ID: 600)

12:20  
**MS02.08: Question & Answer Period**

11:00 - 12:30  
**MS03: Mini Symposium 03 - Imaging**  
Track: Imaging  
Chairs: Ashish Gupta, Canada & Sam Armato, United States  
Room: Provinces II – Level 4

11:00  
**MS03.01: Preclinical Imaging**  
Roslyn Francis, University of Western Australia, Australia

11:15  
**MS03.02: Dynamic Enhancement of Malignant Pleural Mesothelioma with Computed Tomography (CT): A Prospective Clinical Trial**  
Sharyn Katz, University of Pennsylvania Perelman School of Medicine, United States  
(Abstract ID: 825)

11:25  
**MS03.03: Novel Descriptors for Clinical Staging of Malignant Pleural Mesothelioma**  
Hasan Batirel, Marmara University Faculty of Medicine, Turkey  
(Abstract ID: 784)

11:35  
**MS03.04: Novel MRI Methodology for the Assessment of Tumour Volume in MPM**  
Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom  
(Abstract ID: 619)

11:45  
**MS03.05: Deep Learning Applied to the Segmentation of Malignant Pleural Mesothelioma Tumor on Computed Tomography Scans**  
Eyjolfur Gudmundsson, University of Chicago, United States  
(Abstract ID: 655)

11:55  
**MS03.06: CT Radiomics to Predict Outcome in Patients with Malignant Pleural Mesothelioma**  
sabelle Opitz, University Hospital Zürich, Switzerland  
(Abstract ID: 741)

12:05  
**MS03.07: An Update on the Staging System for MPM**  
Valerie Rusch, Memorial Sloan Kettering Cancer Center, United States

12:20  
**MS03.08: Discussant: The Evolving Role of Imaging for Mesothelioma**  
Sam Armato, University of Chicago, United States
Lunch Break
Room: Confederation II/III - Level 4

12:45 – 13:45
ISS01: Industry-Supported Symposium
Room: Confederation I – Level 4
For the detailed program please refer to page 35.

13:45 - 15:15
MS04: Mini Symposium 04 - Towards Personalized Systemic Therapy
Track: Medical Oncology
Chairs: Anna Nowak, Australia & Oluf Røe, Norway
Room: Confederation I – Level 4

13:45
MS04.01: Novel Targets, New Drugs, and New Combinations
Dean Fennell, University of Leicester & University Hospitals of Leicester NHS Trust, United Kingdom

14:00
MS04.02: Loss of BAP1 Function Leads to TRAIL Sensitivity in Malignant Mesothelioma (Abstract ID: 759)
Krishna Kolluri, University College London, United Kingdom

14:10
MS04.03: The Prediction of Resistance to Chemotherapy Using Somatic Copy Number Variation in Mesothelioma (PRiSM) Study: An Update (Abstract ID: 745)
Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom

14:20
MS04.04: Genomic Mechanisms Underpinning BAP1 Loss in Mesotheliomas from Patients Treated with the EZH2 Inhibitor Tazemetostat (Abstract ID: 647)
Dean Fennell, University of Leicester & Leicester University Hospitals, United Kingdom

14:30
MS04.05: PARP Inhibitors as Single Agent or with Temozolomide against Primary Mesothelioma Cell Lines with BAP1 Mutations (Abstract ID: 771)
Daniel Rathkey, National Institutes of Health, United States

14:40
MS04.06: Expression of FGFRs and Evaluation of Efficacy of Different TKIs against FGFR1-4 in MPM (Abstract ID: 790)
Gregor Vlasic, University Clinic Golnik, Slovenia

14:50
MS04.07: Discussant
Arnaud Scherpereel, Hospital of the University of Lille, France

15:00
MS04.08: What Do We Know about Targeting Metabolism in Mesothelioma?
Luciano Mutti, University of Salford, United Kingdom

13:45 - 15:15
MS05: Mini Symposium 05 - Drivers of Mesothelioma Initiation / Progression
Track: Basic Science
Chairs: Courtney Broaddus, United States & Licun Wu, Canada
Room: Provinces I – Level 4

13:45
MS05.01: Assessing the Carcinogenic Potential of Asbestos and Asbestiform Fibres in MexTAG Mice (Abstract ID: 630)
Scott Fisher, National Centre for Asbestos Related Diseases (NCARD), Australia

13:55
MS05.02: Implication of ADAM10 Protease in Malignant Pleural Mesothelioma (Abstract ID: 519)
Marine Bellefroid, University of Liege, Belgium

14:05
MS05.03: TAZ Activation by NF2-Hippo Pathway Dysregulation Induces Cytokine Expression and Provides Growth Advantage to Mesothelioma (Abstract ID: 580)
Yoshitaka Sekido, Aichi Cancer Center Research Institute, Japan

14:15
MS05.04: Early Events during Asbestos-Driven Tumor Development (Abstract ID: 611)
Emanuela Felley-Bosco, University Hospital Zürich, Switzerland
14:25  MS05.05: Evaluation of RAN Gene using siRNA and CRISPR/CAS9 in Malignant Pleural Mesothelioma (Abstract ID: 621)  
     Irene Dell'Anno, University of Pisa, Italy

14:35  MS05.06: A Potential Therapeutic Strategy for Malignant Mesothelioma with Heparanase Inhibitors (Abstract ID: 673)  
     Moshe Lapidot, Brigham and Women's Hospital, United States

14:45  MS05.07: Small Molecule Transcriptional Suppression of PRMT5 Induces Synthetic Lethality in MTAP-Negative Mesothelioma (Abstract ID: 734)  
     Sara Busacca, University of Leicester, United Kingdom

14:55  MS05.08: Depletion of M2 Mesothelioma-Associated Macrophages May Decrease Mesothelioma Cell Stemness Leading to Lessened Tumorigenesis (Abstract ID: 563)  
     Licun Wu, Toronto General Hospital and Princess Margaret Cancer Centre, Canada

15:05  MS05.09: Discussant  
     Steven Mutsaers, University of Western Australia, Australia

13:45 - 15:15  
**MS06: Mini Symposium 06 - Malignant Effusions**  
Track: Symptom Control / Palliative Care  
Chairs: Fraser Brims, Australia & Dan Sterman, United States  
Room: Provinces II – Level 4

13:45  MS06.01: Debate: What is the Optimal Approach to Manage Malignant Pleural Effusions?  
     **Medical Management is Best**  
     Nick Maskell, University of Bristol, United Kingdom  
     **Surgical Management is Best**  
     Marc De Perrot, Toronto General Hospital and Princess Margaret Cancer Center, Canada

14:15  MS06.02: The Prevalence of Pleural Effusions at Presentation: A Prospective Cohort of 229 Patients with Malignant Pleural Mesothelioma (Abstract ID: 549)  
     Anna Bibby, University of Bristol, United Kingdom

14:25  MS06.03: Is Pleural Infection Associated with Longer Survival in Mesothelioma? A Cohort Study Using Hospital Episode Statistics Data (Abstract ID: 757)  
     Anna Bibby, University of Bristol, United Kingdom

14:35  MS06.04: Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters (Abstract ID: 833)  
     Sarah Hosseini, The Ottawa Hospital, Canada

14:45  MS06.05: Diagnostic Value of Pleural Effusion Tumor Markers for Malignant Pleural Mesothelioma (Abstract ID: 751)  
     Yasuhiro Hida, Hokkaido University Hospital, Japan

14:55  MS06.06: Question & Answer Period

15:15 - 16:00  
**Poster Viewing with Coffee**  
Room: Confederation II/III - Level 4
16:00 - 17:30  
**PL02: Plenary Session 02 - Immunotherapy of Mesothelioma**
Track: Medical Oncology  
Chairs: Scott Laurie, Canada & Jeremy Steele, United Kingdom  
Room: Confederation I – Level 4

16:00  
**PL02.01: Characterization of PD-L1 Protein Expression in a Large Cohort of Malignant Pleural Mesothelioma** (Abstract ID: 699)  
Assunta De Rienzo, Brigham and Women's Hospital, United States

16:10  
**PL02.02: Pathological Predictors of Response to Immunotherapy in MPM**  
Françoise Galateau-Sallé, Centre Léon Bérard, France

16:25  
**PL02.03: Second- or Third-Line Nivolumab vs. Nivo + Ipiilimumab in Mesothelioma: Final Results of IFCT-1501 MAPS2 Randomized Phase 2 Trial** (Abstract ID: 540)  
Arnaud Scherpereel, Hospital of the University of Lille, France

16:35  
**PL02.04: Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma: Final Results of a Phase II Study (INITIATE)** (Abstract ID: 669)  
Paul Baas, Netherlands Cancer Institute, Netherlands

16:45  
**PL02.05: DREAM: A Phase 2 Trial of DuRvalumab with First-Line chEmotherApy in Mesothelioma with a Safety Lead-In** (Abstract ID: 536)  
Anna Nowak, University of Western Australia, Australia

16:55  
**PL02.06: Real-World Outcomes for Patients Treated with Pembrolizumab (Pembro) for Relapsed Malignant Pleural Mesothelioma (MPM)** (Abstract ID: 796)  
Kenneth O'Byrne, Queensland University of Technology, Australia

17:05  
**PL02.07: Discussion: The Evolving Landscape of Immunotherapy Trials for Mesothelioma**  
Arnaud Scherpereel, Hospital of the University of Lille, France

17:20  
**PL02.08: Question & Answer Period**

---

17:30 - 18:30  
**Poster Mixer with Poster Discussions**  
Room: Confederation II/III - Level 4
**PL03: Plenary Session 03 - Asbestos Control Perspectives: Before the Ban, the Ban, after the Ban**

Track: Patient Advocacy  
Chairs: Paul Wheatley-Price, Canada & Sam Armato, United States  
Room: Confederation I - Level 4  

08:45 - 09:00  
**PL03.01**: Surviving and Dying with Canadian Asbestos Hidden in Our Lungs. A Belgian World Activist Speaks Out  
Eric Jonckheere, Belgian Asbestos Victims’ Association, Belgium  

09:00 - 09:15  
**PL03.02**: Advocating for a Ban in Emerging Economies: The Colombian Experience  
Guilermo Villamizar, Fundclas, Colombia  

09:15 - 09:30  
**PL03.03**: After the Asbestos Ban – the Australian Experience  
Peter Tighe, Australian Asbestos Safety and Eradication Agency, Australia  

09:30 - 09:45  
**PL03.04**: It Really Does Matter: Encouraging Workers Diagnosed with Mesothelioma to Apply for Compensation Just Makes Sense  
(Abstract ID: 819)  
Liane Murphy, The Ottawa Hospital, Canada  

09:45 - 10:00  
**PL03.05**: How We Achieved an Asbestos Ban in Canada – and Where We Need to Go from Here  
(Abstract ID: 777)  
Alec Farquhar, Ontario Office of the Worker Adviser, Canada  

10:00 - 10:15  
**PL03.06**: Implementing a Ban  
Bob Blakely, Canada’s Building Trades Unions, Canada  

**Poster Viewing with Coffee**  
Room: Confederation II/III - Level 4  

11:00 - 11:30  
**MS07: Mini Symposium 07 - Translating Clinical Knowledge into Clinical Action**  
Track: Nursing  
Chairs: Anastasia Bykova, Canada & Liz Darlison, United Kingdom  
Room: Confederation I - Level 4  

11:00  
**MS07.01**: Medical Oncology Treatment Modalities and Case Study  
Buerkle Rose, University of Chicago, United States  

11:15  
**MS07.02**: Radiation Oncology Treatment Modalities and Case Study  
Erica Glass, Maryland Proton Treatment Center, United States  

11:30  
**MS07.03**: Surgical Treatment Modalities and Case Study  
Melissa Culligan, University of Maryland School of Medicine, United States  

11:45  
**MS07.04**: Receiving a Diagnosis of MEOthelioma (RADIO Meso): Improving the Patient Experience  
(Abstract ID: 546 – Young Investigator Award Winner)  
Bethany Taylor, The University of Sheffield, United Kingdom  

11:55  
**MS07.05**: A Collaborative Approach to a Successful Support Group for Mesothe-lioma Patients and Carers  
(Abstract ID: 718)  
Lorraine Creech, Glenfield Hospital, United Kingdom  

12:05  
**MS07.06**: National Lung Cancer Audit: Pleural Mesothelioma Report 2016. The Influence of Mesothelioma UK Clinical Nurse Specialists  
(Abstract ID: 766)  
Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom  

12:15  
**MS07.07**: Question & Answer Period
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>MS08: Mini Symposium 08 - Radiation Oncology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Track:</strong> Radiation Oncology</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Robert MacRae, Canada &amp; Andreas Rimner, United States</td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Provinces I – Level 4</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>MS08.01: SYSTEMS-2: A Phase II Randomised Study of Radiotherapy</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dose Escalation for Pain Control in Malignant Pleural Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 554)</td>
</tr>
<tr>
<td></td>
<td>Miranda Ashton, University of Glasgow, United Kingdom</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>MS08.02: Stereotactic Body Radiation Therapy as Salvage Therapy</strong></td>
</tr>
<tr>
<td></td>
<td><em>for Oligometastasised Pleural Mesothelioma after Multimodal Therapy</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 602)</td>
</tr>
<tr>
<td></td>
<td>Olivia Lauk, University Hospital Zurich, Switzerland</td>
</tr>
<tr>
<td>11:20</td>
<td><strong>MS08.03: Radical/Salvage Approaches</strong></td>
</tr>
<tr>
<td></td>
<td>Charles Simone, Maryland Proton Treatment Center, United States</td>
</tr>
<tr>
<td>11:35</td>
<td><strong>MS08.04: Toxicities and Outcomes of Whole Pleural Intensity-</strong></td>
</tr>
<tr>
<td></td>
<td><em>Modulated Proton Therapy for Lung-Intact Malignant Pleural Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 767)</td>
</tr>
<tr>
<td></td>
<td>Jason Molitoris, University of Maryland Medical Center, United States</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>MS08.05: An Investigation of Hybrid Planning with Multi Criteria</strong></td>
</tr>
<tr>
<td></td>
<td><em>Optimization for Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 557)</td>
</tr>
<tr>
<td></td>
<td>Timothy Mitchell, Beatson West of Scotland Institute, United Kingdom</td>
</tr>
<tr>
<td>11:55</td>
<td><strong>MS08.06: Understanding the Immune Response to Radiotherapy in</strong></td>
</tr>
<tr>
<td></td>
<td><em>a Dual Tumour Model of Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 565)</td>
</tr>
<tr>
<td></td>
<td>Wesley Wilson, University of Western Australia, Australia</td>
</tr>
<tr>
<td>12:05</td>
<td><strong>MS08.07: Palliative Radiation</strong></td>
</tr>
<tr>
<td></td>
<td>Noelle O'Rourke, NHS Greater Glasgow and Clyde, United Kingdom</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>MS08.08: Question &amp; Answer Period</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>MS08: Mini Symposium 08 - Radiation Oncology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Track:</strong> Radiation Oncology</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Robert MacRae, Canada &amp; Andreas Rimner, United States</td>
</tr>
<tr>
<td></td>
<td><strong>Room:</strong> Provinces I – Level 4</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>MS08.01: SYSTEMS-2: A Phase II Randomised Study of Radiotherapy</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dose Escalation for Pain Control in Malignant Pleural Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 554)</td>
</tr>
<tr>
<td></td>
<td>Miranda Ashton, University of Glasgow, United Kingdom</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>MS08.02: Stereotactic Body Radiation Therapy as Salvage Therapy</strong></td>
</tr>
<tr>
<td></td>
<td><em>for Oligometastasised Pleural Mesothelioma after Multimodal Therapy</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 602)</td>
</tr>
<tr>
<td></td>
<td>Olivia Lauk, University Hospital Zurich, Switzerland</td>
</tr>
<tr>
<td>11:20</td>
<td><strong>MS08.03: Radical/Salvage Approaches</strong></td>
</tr>
<tr>
<td></td>
<td>Charles Simone, Maryland Proton Treatment Center, United States</td>
</tr>
<tr>
<td>11:35</td>
<td><strong>MS08.04: Toxicities and Outcomes of Whole Pleural Intensity-</strong></td>
</tr>
<tr>
<td></td>
<td><em>Modulated Proton Therapy for Lung-Intact Malignant Pleural Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 767)</td>
</tr>
<tr>
<td></td>
<td>Jason Molitoris, University of Maryland Medical Center, United States</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>MS08.05: An Investigation of Hybrid Planning with Multi Criteria</strong></td>
</tr>
<tr>
<td></td>
<td><em>Optimization for Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 557)</td>
</tr>
<tr>
<td></td>
<td>Timothy Mitchell, Beatson West of Scotland Institute, United Kingdom</td>
</tr>
<tr>
<td>11:55</td>
<td><strong>MS08.06: Understanding the Immune Response to Radiotherapy in</strong></td>
</tr>
<tr>
<td></td>
<td><em>a Dual Tumour Model of Mesothelioma</em></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 565)</td>
</tr>
<tr>
<td></td>
<td>Wesley Wilson, University of Western Australia, Australia</td>
</tr>
<tr>
<td>12:05</td>
<td><strong>MS08.07: Palliative Radiation</strong></td>
</tr>
<tr>
<td></td>
<td>Noelle O'Rourke, NHS Greater Glasgow and Clyde, United Kingdom</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>MS08.08: Question &amp; Answer Period</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td><strong>MS10: Mini Symposium 10 - Biomarkers of MPM: Inflammation, Antigens, T Cells and More</strong>&lt;br&gt;Track: Basic Science&lt;br&gt;Chairs: Jan van Meerbeeck, Belgium &amp; Jenette Creaney, Australia&lt;br&gt;Room: Les Saisons – Level 3</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>MS10.01: Serum miRNA Profiling of Malignant Pleural Mesothelioma and Early Diagnosis: A Massive Parallel Sequencing Approach</strong>&lt;br&gt;(Abstract ID: 562 – Young Investigator Award Winner)&lt;br&gt;Elisabetta Casalone, Italian Institute for Genomic Medicine, Italy</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>MS10.02: Preliminary Results of the Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) Study</strong>&lt;br&gt;(Abstract ID: 620)&lt;br&gt;Kevin Blyth, Queen Elizabeth University Hospital, United Kingdom</td>
</tr>
<tr>
<td>11:20</td>
<td><strong>MS10.03: Experimental Model of Human Malignant Mesothelioma in Athymic Mice for in vivo Evaluation of Therapy Using MIF/CD74 Inhibitor</strong>&lt;br&gt;(Abstract ID: 616)&lt;br&gt;Veronique Serre-Beinier, University Hospitals and Medical University of Geneva, Switzerland</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>MS10.04: Time Course of Myeloid-Derived Suppressor Cells and M2 Macrophages in Murine Malignant Pleural Mesothelioma Microenvironment</strong>&lt;br&gt;(Abstract ID: 590)&lt;br&gt;Mikihiro Kohno, Toronto General Research Institute, Canada</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>MS10.05: Chrysotile-Induced Malignant Mesothelioma in Genetically Engineered Mouse Models</strong>&lt;br&gt;(Abstract ID: 811)&lt;br&gt;Yuaraj Kadariya, Fox Chase Cancer Center, United States</td>
</tr>
<tr>
<td>11:50</td>
<td><strong>MS10.06: Immunogenomic Determinants of Response to PD-1 Blockade in Malignant Pleural Mesothelioma</strong>&lt;br&gt;(Abstract ID: 746)&lt;br&gt;Hyun-Sung Lee, Baylor College of Medicine, United States</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>MS10.07: Phenotypic and Functional Analysis of Malignant Mesothelioma Tumor-Infiltrating Lymphocytes (TILs)</strong>&lt;br&gt;(Abstract ID: 639)&lt;br&gt;Astero Klampatsa, University of Pennsylvania, United States</td>
</tr>
<tr>
<td>12:10</td>
<td><strong>MS10.08: Identification of the Molecular Signature of Intratumor Tregs and of Tumor-Derived Immunosuppressive Signals</strong>&lt;br&gt;(Abstract ID: 606)&lt;br&gt;Stefano Biffo, Istituto Nazionale di Genetica Molecolare, Italy</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>MS10.09: Question &amp; Answer Period</strong></td>
</tr>
<tr>
<td>12:30 - 13:45</td>
<td><strong>Lunch Break</strong></td>
</tr>
<tr>
<td>13:45 - 15:15</td>
<td><strong>MS11: Mini Symposium 11 - Advocacy and Screening</strong>&lt;br&gt;Track: Patient Advocacy&lt;br&gt;Chairs: Christopher Lee, Canada &amp; Eudice Goldberg, Canada&lt;br&gt;Room: Confederation I – Level 4</td>
</tr>
<tr>
<td>13:45</td>
<td><strong>MS11.01: Mesothelioma Advocacy in the 21st Century</strong>&lt;br&gt;(Abstract ID: 729)&lt;br&gt;Linda Reinstein, Asbestos Disease Awareness Organization, United States</td>
</tr>
<tr>
<td>13:55</td>
<td><strong>MS11.02: Meet the Experts: Evaluation of Speed Dating with Researchers on Action Mesothelioma Day in the UK</strong>&lt;br&gt;(Abstract ID: 670)&lt;br&gt;Simon Bolton, Harrogate &amp; District NHS Foundation Trust, United Kingdom</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS11.03: Documentation of Asbestos Exposure in the Medical Records of Patients with Mesothelioma</strong>&lt;br&gt;(Abstract ID: 523)&lt;br&gt;Christopher Lee, BC Cancer Agency, Canada</td>
</tr>
<tr>
<td>14:15</td>
<td><strong>MS11.04: From Support to Social: The Evolution of the Papworth Mesothelioma Support Group</strong>&lt;br&gt;(Abstract ID: 640)&lt;br&gt;Kate Slaven, Papworth Hospital, United Kingdom</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS11.05: Discussant</strong></td>
</tr>
</tbody>
</table>
### Track: Surgery
**Chairs:** Harvey Pass, United States & Donna Maziak, Canada  
**Room:** Provinces I – Level 4  
**13:45 - 15:15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 13:45 | **MS11.06:** Screening for Malignant Pleural Mesothelioma and Early Lung Cancer in Asbestos-Exposed Individuals  
(Abstract ID: 768) | Demetris Patsios, University Health Network, Canada                     |
| 14:00 | **MS12.01:** Progress in Surgical Procedures and Techniques  
(Isabelle Opitz, University Hospital Zürich, Switzerland) | Isabelle Opitz, University Hospital Zürich, Switzerland                 |
| 14:05 | **MS12.02:** The Relationship between Cancer Surgery, Lymph Nodes, Immunotherapy and T Cells  
(Abstract ID: 703) | Jenette Creaney, University of Western Australia, Australia             |
| 14:35 | **MS11.07:** An Exhaled Breath Biopsy Earmarks Exclusive Screening for Malignant Pleural Mesothelioma  
(Abstract ID: 567) | Kevin Lamote, University of Antwerp, Belgium                           |
| 14:40 | **MS12.05:** Pleurectomy/Decortication and Intraoperative Intrapleural Hyperthermic Cisplatin Perfusion for Malignant Pleural Mesothelioma  
(Abstract ID: 582) | Kenichi Okubo, Tokyo Medical and Dental University, Japan              |
| 15:05 | **MS12.03:** Efficacy of Neoadjuvant Chemotherapy Followed by Resection in Pleural Mesothelioma with Positive Cervical Mediastinoscopy  
(Abstract ID: 700) | Sristi Sharma, University of Colorado, United States                  |
| 15:10 | **MS12.04:** Impact of Different Treatment Modalities on Survival in Malignant Pleural Mesothelioma: Results of Case Control Analysis  
(Abstract ID: 754) | Muzaffer Metintas, Eskisehir Osmangazi University, Turkey              |
| 15:15 | **MS12.06:** Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients: A French Single-Center Cohort  
(Abstract ID: 748) | Muzaffer Metintas, Eskisehir Osmangazi University, Turkey              |
| 15:20 | **MS12.07:** Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma: Initial Single-Center Experience  
(Abstract ID: 727) | Servet Bölükbas, Kliniken Essen-Mitte, Germany                        |

### Track: Basic Science
**Chairs:** Demetris Patsios, Canada & Sjaak Burgers, Netherlands  
**Room:** Provinces II – Level 4  
**13:45 - 15:15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 14:35 | **MS13.01:** Overview of Early Trials / Data on Non-PD-1 Drugs  
(Anna Nowak, University of Western Australia, Australia) | Anna Nowak, University of Western Australia, Australia                |
| 14:00 | **MS13.02:** Overview of CAR-T Therapy for Meso  
(Andrew Haas, University of Pennsylvania Perelman School of Medicine, United States) | Andrew Haas, University of Pennsylvania Perelman School of Medicine, United States |
14:15 MS13.03: Mesothelin-Targeted Immunotoxin LMB-100 Plus Anti-PD-1 Antibody in Syngeneic Mouse Model Expressing Human Mesothelin
(Abstract ID: 763)
Raffit Hassan, National Cancer Institute, United States

14:25 MS13.04: Live-Attenuated, Listeria Monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of MPM
(Abstract ID: 794)
Evan Alley, University of Pennsylvania, United States

14:35 MS13.05: Rearrangement-Related Peptides with Neoantigenic Potential in Malignant Pleural Mesothelioma (Abstract ID: 533)
Aaron Mansfield, Mayo Clinic, United States

14:45 MS13.06: Rational Therapeutic Modulation of the Tumor Microenvironment Sensitizes Cancers to Immune Checkpoint Blockade (Abstract ID: 558 – Young Investigator Award Winner)
Rachael Zemek, University of Western Australia, Australia

14:55 MS13.07: PD1 Checkpoint Blockade Overcomes Upregulation of Multiple Inhibitory Receptors (Abstract ID: 724)
Jordan Dozier, Memorial Sloan Kettering, United States

15:05 MS13.08: Question & Answer Period

13:45 – 15:15 MS14: Mini Symposium 14 - The Roles of miRNA and BAP1
Track: Basic Science
Chairs: Michele Carbone, United States & Penelope Bradbury, Canada
Room: Les Saisons – Level 3

13:45 MS14.01: Elucidating BAP1-microRNA Regulatory Networks in Mesothelioma (Abstract ID: 544)
Judy Coulson, University of Liverpool, United Kingdom

Victor Martinez, BC Cancer Agency, Canada

14:05 MS14.03: Role of miRNA in Mesothelioma Progression
Michaela Kirschner, University Hospital Zurich, Switzerland

14:20 MS14.04: Histopathological and Molecular Characterization of BAP1 in Malignant Pleural Mesothelioma (Abstract ID: 584)
Assunta De Rienzo, Brigham and Women's Hospital, United States

14:30 MS14.05: Discovering and Translating BAP1 Dependencies: Towards Precision Therapy of Mesothelioma (Abstract ID: 740)
Sarah Taylor, University of Liverpool, United Kingdom

14:40 MS14.06: How BAP1 Modulates Gene-Environment Interaction in Carcinogenesis and Renders Tumour Cells Resistant to Chemotherapy (Abstract ID: 674)
Michele Carbone, University of Hawaii Cancer Center, United States

14:50 MS14.08: Question & Answer Period

15:15 - 16:00 Poster Viewing with Coffee
Room: Confederation I/II - Level 4
16:00 - 17:30  **PL04: Plenary Session 04 - The Genome and Epigenetics of Mesothelioma**  
Track: Basic Science  
Chairs: Marie-Claude Jaurand, France & Christina Addison, Canada  
Room: Confederation I – Level 4  

16:00  **PL04.01: Molecular Heterogeneity of Mesothelioma**  
Jean Didier, INSERM, France  

Marc Ladanyi, Memorial Sloan Kettering Cancer Center, United States  

16:30  **PL04.03: The MexTag Collaborative Cross: Identifying the Genetic Basis of Mesothelioma. An Interim Report**  
(Abstract ID: 627)  
Scott Fisher, National Centre for Asbestos Related Diseases (NCARD), Australia  

16:40  **PL04.04: Both Long-Fibre Carbon Nanotubes and Asbestos Alter the Level of DNA Methylation in the Pleura of Exposed Mice**  
(Abstract ID: 761)  
Joaquin Zacarias-Cabeza, Medical Research Council (MRC), United Kingdom  

16:50  **PL04.05: Long-Fibre CNT and Asbestos Induce Pleural Mesothelioma: A Key Role for Epigenetic Mechanisms in Disease Development**  
(Abstract ID: 826)  
Marion MacFarlane, MRC Toxicology Unit, United Kingdom  

17:00  **PL04.06: Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma**  
(Abstract ID: 721)  
Irma Dianzani, HUGEF Human Genetics Foundation, Italy  

17:10  **PL04.07: Question & Answer Period**  

17:15  **PL04.08: Application of CGH in Mesothelioma and its Role in the Identification of New Treatment Targets**  
Michele Carbone, University of Hawaii Cancer Center, United States  

17:30 - 18:30  **Poster Mixer with Poster Discussions**  
Room: Confederation II/III - Level 4
08:45 - 10:15  
**PL05: Plenary Session 05 - Multidisciplinary Management**
Track: Surgery  
Chairs: Paul Baas, Netherlands & Walter Weder, Switzerland  
Room: Confederation I – Level 4

- **08:45**: PL05.01: The Role of Surgery in the Multidisciplinary Management of Mesothelioma in 2018  
  Harvey Pass, New York University, United States

- **09:00**: PL05.02: EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM (Abstract ID: 543 – Young Investigator Award Winner)  
  Jo Raskin, Antwerp University Hospital, Belgium

- **09:10**: PL05.03: Does the Administration of Total Parenteral Nutrition Following Extended Pleurectomy Decortication Offer Any Benefit? (Abstract ID: 663)  
  Alan Dawson, Glenfield Hospital, United Kingdom

- **09:20**: PL05.04: Quality of Life is Not Deteriorated After (Extended) Pleurectomy/Decortication vs. Pneumonectomy in Mesothelioma Patients (Abstract ID: 589)  
  Olivia Lauk, University Hospital Zürich, Switzerland

- **09:30**: PL05.05: Debate: When is the Best Time to Administer RT?  
  **Pre-Op**  
  John Cho, University Health Network, Canada

  **Post-Op**  
  Andreas Rimner, Memorial Sloan Kettering, United States

- **09:55**: PL05.06: Outcomes for Patients Treated with Surgery for Mesothelioma After Radiation Therapy: SMART Study Interim Results (Abstract ID: 660)  
  John Cho, University Health Network, Canada

- **10:05**: PL05.07: Question & Answer Period

10:15 - 11:00  
**Poster Viewing with Coffee**
Room: Confederation II/III - Level 4

11:00 - 12:30  
**MS15: Mini Symposium 15 - Surgical Palliation**
Track: Surgery  
Chairs: Joe Friedberg, United States & Marc De Perrot, Canada  
Room: Confederation I – Level 4

- **11:00**: MS15.01: Diagnosis & Management of Local Recurrence  
  Raphael Bueno, Brigham and Women’s Hospital, United States

- **11:15**: MS15.02: Is There a Role for Purely Palliative Surgery?  
  David Waler, St. Bartholomew Hospital, United Kingdom

- **11:30**: MS15.03: Surgical Management of Malignant Pleural Mesothelioma After Induction Chemotherapy: 18 Years of Single Center Experience (Abstract ID: 592)  
  Olivia Lauk, University Hospital Zürich, Switzerland

- **11:40**: MS15.04: Pleurectomy/Decortication, Intrapleural Betadine, Prophylactic Radiotherapy and Systemic Chemotherapy: Long-Term Results (Abstract ID: 706)  
  Loic Lang-Lazdunski, BUPA Cromwell Hospital, United Kingdom

- **11:50**: MS15.05: The Transition of Quality of Life After Pleurectomy/Decortication for Malignant Pleural Mesothelioma (Abstract ID: 717)  
  Toru Nakamichi, Hyogo College of Medicine, Japan

- **12:00**: MS15.06: The Improving Results of Trimodality Treatment Strategy for Operable Malignant Pleural Mesothelioma (Abstract ID: 552)  
  Kazunori Okabe, Yamaguchi Ube Medical Center, Japan
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td><strong>MS16: Mini Symposium 16 - Interdisciplinary Symptom Control in MPM</strong></td>
</tr>
<tr>
<td></td>
<td>Track: Symptom Control / Palliative Care</td>
</tr>
<tr>
<td></td>
<td>Chairs: Monica Malec, United States &amp; Camille Munro, Canada</td>
</tr>
<tr>
<td></td>
<td>Room: Provinces I – Level 4</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>MS16.01: Psychological Aspects of Management Dyspnea</strong></td>
</tr>
<tr>
<td></td>
<td>Amy Siston, University of Chicago, United States</td>
</tr>
<tr>
<td>11:15</td>
<td><strong>MS16.02: Case-Based Complex Pain Issues in MPM</strong></td>
</tr>
<tr>
<td></td>
<td>Monica Malec, University of Chicago, United States</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>MS16.03: A Multicentre RCT Assessing Regular Early Specialist Palliative Care in Malignant Pleural Mesothelioma: RESPECT-MESO</strong> (Abstract ID: 676)</td>
</tr>
<tr>
<td></td>
<td>Fraser Brims, Sir Charles Gairdner Hospital, Australia</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>MS16.04: MesoTRAP: A Feasibility Study Comparing VAT Pleurectomy with IPC for Trapped Lung in Pleural Mesothelioma</strong> (Abstract ID: 713)</td>
</tr>
<tr>
<td></td>
<td>Robert Rintoul, University of Cambridge, United Kingdom</td>
</tr>
<tr>
<td>11:50</td>
<td><strong>MS16.05: MARS 2 Qualitative Assessment Study: Implications of Findings for Post-Surgical Follow-Up Care</strong> (Abstract ID: 638)</td>
</tr>
<tr>
<td></td>
<td>Angela Tod, The University of Sheffield, United Kingdom</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>MS16.06: A UK General Hospital's Experience with Malignant Pleural Mesothelioma in a High-Incidence Area</strong> (Abstract ID: 601)</td>
</tr>
<tr>
<td></td>
<td>Lewis Standing, Northumbria Healthcare Trust, United Kingdom</td>
</tr>
<tr>
<td>12:10</td>
<td><strong>MS16.07: Question &amp; Answer Period</strong></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>MS17: Mini Symposium 17 - Benign vs. Malignant Mesothelial Proliferations and Subtypes of MPM</strong></td>
</tr>
<tr>
<td></td>
<td>Track: Pathology</td>
</tr>
<tr>
<td></td>
<td>Chairs: Harmon Sekhon, Canada &amp; Françoise Galateau-Sallé, France</td>
</tr>
<tr>
<td></td>
<td>Room: Provinces II – Level 4</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>MS17.01: A Multi-Institutional Evaluation of Pleural Biphasic Mesothelioma by the International Mesothelioma Panel: New Insights</strong> (Abstract ID: 774)</td>
</tr>
<tr>
<td></td>
<td>François Galateau-Sallé, Centre Leon Berard, France</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>MS17.02: New Data of the Molecular Subtypes of Mesothelioma</strong></td>
</tr>
<tr>
<td></td>
<td>Lynnette Fernandez-Cuesta, International Agency for Research on Cancer, France</td>
</tr>
<tr>
<td>11:25</td>
<td><strong>MS17.03: Differential Diagnosis of Malignant Pleural Mesothelioma: Effectiveness of a Gene Expression Panel on Pleural Effusions</strong> (Abstract ID: 607)</td>
</tr>
<tr>
<td></td>
<td>Rossella Bruno, University of Pisa, Italy</td>
</tr>
<tr>
<td>11:35</td>
<td><strong>MS17.04: Image-Guided Percutaneous Pleural Biopsy Diagnostic Yield and Accuracy for Benign and Malignant Pleural Lesions</strong> (Abstract ID: 831)</td>
</tr>
<tr>
<td></td>
<td>Joao Inacio, The University of Ottawa, Canada</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>MS17.05: Immunohistochemical Detection of MTAP or BAP1 Protein Loss in Tissues and Cell Blocks for Diagnosis of Mesothelioma</strong> (Abstract ID: 709)</td>
</tr>
<tr>
<td></td>
<td>Kazuki Nabeshima, Fukuoka University School of Medicine, Japan</td>
</tr>
<tr>
<td>11:55</td>
<td><strong>MS17.06: Gene Expression Profiling vs. p16 and BAP1 Evaluation in the Differential Diagnosis of Mesothelial Proliferations</strong> (Abstract ID: 609)</td>
</tr>
<tr>
<td></td>
<td>Greta Ali, Azienda Ospedaliero Universitaria, Italy</td>
</tr>
</tbody>
</table>
### SCIENTIFIC PROGRAM

**Saturday, May 5, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:05</td>
<td><strong>MS17.07: Correlation Between Benign and Malignant Mesothelial Proliferation</strong></td>
</tr>
<tr>
<td></td>
<td>Andreas Churg, Vancouver General Hospital, Canada</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>MS17.08: Question &amp; Answer Period</strong></td>
</tr>
<tr>
<td>12:30 - 14:00</td>
<td><strong>Lunch Break</strong></td>
</tr>
<tr>
<td></td>
<td>Room: Confederation II/III - Level 4</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td><strong>PL06: Plenary Session 06 - Immunotherapy, Bench to Bedside</strong></td>
</tr>
<tr>
<td></td>
<td>Track: Basic Science</td>
</tr>
<tr>
<td></td>
<td>Chairs: Penelope Bradbury, Canada &amp; Luciano Mutti, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Room: Confederation I - Level 4</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>PL06.01: How Recent Insights into the Immune Environment in Mesothelioma are Informing the Next Generation of Immunotherapies</strong></td>
</tr>
<tr>
<td></td>
<td>Jenette Creaney, University of Western Australia, Australia</td>
</tr>
<tr>
<td>14:15</td>
<td><strong>PL06.02: Epigenetics for Immunotherapy: Application to Mesothelioma</strong></td>
</tr>
<tr>
<td></td>
<td>Christophe Blanquart, CRCINA, France</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>PL06.03: Neoantigen Abundance and MHC Protein Expression Underlie Immunogenicity in Malignant Pleural Mesothelioma</strong></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 785)</td>
</tr>
<tr>
<td></td>
<td>Hyun-Sung Lee, Baylor College of Medicine, United States</td>
</tr>
<tr>
<td>14:40</td>
<td><strong>PL06.04: A Modified Measles Virus Exhibits Enhanced Oncolytic and Immunotherapeutic Properties Against Human Mesothelioma Cells</strong></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 651)</td>
</tr>
<tr>
<td></td>
<td>Nicolas Boisgerault, CRCINA Cancer Research Center, France</td>
</tr>
<tr>
<td>14:50</td>
<td><strong>PL06.05: Genetic Blockade of the Protein Tyrosine Phosphatase SHP1 Augments CAR T-Cell Activity against PDL1-Expressing Solid Tumors</strong></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 526)</td>
</tr>
<tr>
<td></td>
<td>Edmund Moon, University of Pennsylvania Perelman School of Medicine, United States</td>
</tr>
<tr>
<td>15:00</td>
<td><strong>PL06.06: Immune Profiling Identifies Differential Expression of Complement Pathway Genes Related to Molecular Clusters of Mesothelioma</strong></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 586)</td>
</tr>
<tr>
<td></td>
<td>David Severson, Brigham and Women's Hospital, United States</td>
</tr>
<tr>
<td>15:10</td>
<td><strong>PL06.07: Diagnostic and Prognostic Evaluation of M-CSF and IL-34 Cytokines in Pleural Effusions from Mesothelioma Patients</strong></td>
</tr>
<tr>
<td></td>
<td>(Abstract ID: 613)</td>
</tr>
<tr>
<td></td>
<td>Thibault Blondy, CRCINA, France</td>
</tr>
<tr>
<td>15:20</td>
<td><strong>PL06.08: Question &amp; Answer Period</strong></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td><strong>Closing Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Room: Confederation I - Level 4</td>
</tr>
</tbody>
</table>
POSTER LISTINGS

Posters will be displayed for the duration of the Conference during Exhibition Hours. Presenters are required to stand by their poster during BOTH Poster Mixer with Poster Discussion Sessions (Thursday, May 3 & Friday, May 4 - 17:30–18:30) to answer questions from Conference delegates. Please note that two poster presentations will be awarded the Best Poster Awards during the Presidential Closing Address on Saturday, May 5.

Poster Mixer with Poster Discussions
Thursday, May 3 & Friday, May 4 - 17:30–18:30
Room: Confederation II/III - Level 4

Poster Setup and Take Down
Setup hours:
Thursday, May 3, 2018, 08:00–11:00
Take down hours:
Saturday, May 5, 2018, 14:00–17:00; any posters not removed by 17:00 will be discarded.

Track: Basic Science

PP01.01: Functional Implication of SETD2 Tumor Suppressor Gene in Mesothelial Carcinogenesis
Lisa Quetel, Inserm UMR-1162, France

PP01.02: Intra-Tumoral Molecular Heterogeneity in Malignant Pleural Mesothelioma
François Montagne, Inserm UMR-1162, France

PP01.03: Role of GITRL-GITR System in Promoting Proliferation of Malignant Mesothelioma
Mei-Lin Chan, Toronto General Hospital and Princess Margaret Cancer Centre, Canada

PP01.04: Malignant Pleural Mesothelioma Interactome with 367 Novel Protein-Protein Interactions
Madhavi Ganapathiraju, University of Pittsburgh, United States

PP01.05: Novel Insights on Disease Biology from Malignant Pleural Mesothelioma Interactome
Madhavi Ganapathiraju, University of Pittsburgh, United States

PP01.06: Mesothelioma Cells Exhibit Addiction to the Anti-Apoptotic Protein Bcl-xL and Are Sensitized to Radiation by BH3-Mimetics
Miranda Ashton, University of Glasgow, United Kingdom

PP01.07: Ubiquitin-Dependent Regulation of DNA Damage Tolerance in Mesothelioma
Ludovic Dhont, University of Liège, Belgium

PP01.08: “Asbestos-Free” Mesothelioma: Evaluating the Carcinogenicity of Cleavage Fragments following Hill’s Criteria
Joan Steffen, Never Again Consulting, United States

PP01.09: Calretinin Promotes Invasiveness and EMT in Mesothelioma Cells Involving the Activation of the FAK Signaling Pathway
Janine Wörthmüller, University of Fribourg, Switzerland

PP01.10: Evaluation of Antibody Drug Conjugates Targeting ST4 in Mesothelioma
Laurel Schunselaar, The Netherlands Cancer Institute, Netherlands

PP01.11: Aclarubicin as a Promising Novel Therapeutic Option in Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.12: Col3A1: A New Immunohistological Marker for Malignant Pleural Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.13: Brain-Derived Neurotrophic Factor (BDNF): A New Soluble Biomarker for Malignant Pleural Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.14: Assessment of New HDAC Inhibitors for Immunotherapy of Malignant Pleural Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.15: A 3D Explant Model Demonstrates the Therapeutic Efficacy of Newly Developed BH3-Mimetics
Xiao-Ming Sun, University of Leicester, United Kingdom

PP01.16: Allogeneic Antibody Therapy for Malignant Mesothelioma
Hee-Jin Jang, Baylor College of Medicine, United States

PP01.17: Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
Vlijem Kovac, Institute of Oncology Ljubljana, Slovenia

PP01.18: Targeting Cullin Ubiquitin Ligase in Malignant Pleural Mesothelioma
Michaela Kirschner, University Hospital Zürich, Switzerland

PP01.19: A Combined microRNA-Clinical Score as Prognostic Factor for Malignant Pleural Mesothelioma
Michaela Kirschner, University Hospital Zürich, Switzerland

PP01.20: Anti-Tumor Effect of Curcumin Alone or in Combination with Cisplatin-Based Chemotherapy in a Mouse Mesothelioma Model
Chengke Zhang, The Second Hospital of Shandong University, China
POSTER LISTINGS

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>PP01.21</td>
<td>Targeting Protein Synthesis Reshapes Bioenergetics of Malignant Mesothelioma Primary Cells and Overcomes Chemo-Resistance</td>
<td>Stefano Grosso, University of Leicester, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>PP01.22</td>
<td>Effects of Dexamethasone Co-Medication on Chemo-Immunotherapy Treatment in Murine Mesothelioma Models</td>
<td>Anna Nowak, University of Western Australia, Australia</td>
<td></td>
</tr>
<tr>
<td>PP01.23</td>
<td>The Identification of a CD8+ T Cell Response to a Predicted Neoantigen in a Malignant Mesothelioma Patient</td>
<td>Sophie Sneddon, National Centre for Asbestos Related Diseases, Australia</td>
<td></td>
</tr>
<tr>
<td>PP01.24</td>
<td>DKK1 as a Novel Therapeutic Target in Mesothelioma</td>
<td>Alice Guazzelli, University of Salford, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>PP01.25</td>
<td>An MDM2 Inhibitor Achieves Synergistic Cytotoxicity with Oncolytic Adenoviruses on Mesothelioma with the Wild-Type p53 Gene</td>
<td>Masatoshi Tagawa, Chiba Cancer Center Research Institute, Japan</td>
<td></td>
</tr>
<tr>
<td>PP01.26</td>
<td>The Retinoblastoma Family Protein RBL2/p130 Induces Apoptosis in Mesothelioma Cells upon Different Antitumoral Treatments</td>
<td>Francesca Pentimalli, National Cancer Institute of Naples Pasfoud Foundation, Italy</td>
<td></td>
</tr>
<tr>
<td>PP01.27</td>
<td>Precision Cut Tissue Slices (PCTS) of Human Mesotheliomas as a Model for Testing Immuno-Modulatory Compounds Ex Vivo</td>
<td>Astro Klampatsa, University of Pennsylvania, United States</td>
<td></td>
</tr>
<tr>
<td>PP01.28</td>
<td>Do Mutated Mesothelioma Neo-Antigens Have the Potential to be Effective as Treatment Vaccines?</td>
<td>Jenette Creaney, University of Western Australia, Australia</td>
<td></td>
</tr>
<tr>
<td>PP01.29</td>
<td>Whole Genome Sequencing of Malignant Pleural Mesothelioma</td>
<td>Jenette Creaney, University of Western Australia, Australia</td>
<td></td>
</tr>
<tr>
<td>PP01.30</td>
<td>An Asbestos-Exposed Mesothelioma Family without Evidence for a BAP1 Predisposing Mutation</td>
<td>Marieke Hylebos, University of Antwerp, Belgium</td>
<td></td>
</tr>
<tr>
<td>PP01.31</td>
<td>Genetic Polymorphisms of PD-L1 May Influence Response to Platinum-Based Chemotherapy in Malignant Mesothelioma</td>
<td>Vita Dolzan, University of Ljubljana, Slovenia</td>
<td></td>
</tr>
<tr>
<td>PP01.32</td>
<td>Oncogenic Features of KDM4A Histone Demethylase in Mesothelioma</td>
<td>Moshe Lapidot, Brigham and Women’s Hospital, United States</td>
<td></td>
</tr>
<tr>
<td>PP01.33</td>
<td>Upregulation of Wnt Family Proteins May Limit Efficacy of FAK Tyrosine Kinase Inhibitors in Mesothelioma</td>
<td>Christina Addison, Ottawa Hospital Research Institute, Canada</td>
<td></td>
</tr>
<tr>
<td>PP01.34</td>
<td>The FAK Inhibitor BI853520 Exerts Anti-Tumor Activity in Malignant Pleural Mesothelioma</td>
<td>Alireza Hoda, Medical University of Vienna, Austria</td>
<td></td>
</tr>
<tr>
<td>PP01.35</td>
<td>Inhibition of Autophagy Initiation Potentiates Chemosensitivity in Mesothelioma</td>
<td>Carlo Follo, University of California San Francisco, United States</td>
<td></td>
</tr>
<tr>
<td>PP01.36</td>
<td>Assessing the Impact of Voluntary Exercise on Tumour Growth and Treatment in Pre-Clinical Models of Mesothelioma</td>
<td>Scott Fisher, National Centre for Asbestos Related Diseases, Australia</td>
<td></td>
</tr>
<tr>
<td>PP01.37</td>
<td>Partial Antiviral Type I Interferon Response by Mesothelioma Cells Sensitive to the Oncolytic Activity of Measles Virus</td>
<td>Jean-François Fonteneau, INSERM, France</td>
<td></td>
</tr>
<tr>
<td>PP01.38</td>
<td>How Pleural Mesothelioma Nodules Remodel Their Surroundings to Vascularize and Grow: Findings from Orthotopic Mouse Models</td>
<td>Ildikó Kovacs, National Korányi Institute of Pulmonology, Hungary</td>
<td></td>
</tr>
<tr>
<td>PP01.39</td>
<td>Whole-Genome RNAi Screen Reveals a Potential Therapy Depending on BAP1 Status in Malignant Pleural Mesothelioma</td>
<td>Agata Okonska, University Hospital Zürich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>PP01.40</td>
<td>Suppression of SIRT1 Sensitizes BAP1 Wild-Type Malignant Pleural Mesothelioma Cells to the EZH2 Inhibitor EPZ6438</td>
<td>Laura Moro, University of Piemonte Orientale, Italy</td>
<td></td>
</tr>
<tr>
<td>PP01.41</td>
<td>Inhibition of Lysine Methyltransferase EZH2 Improves Tumoricidal Activity of Macrophages towards Mesothelioma Cells</td>
<td>Malik Hamaidia, University of Liège, Belgium</td>
<td></td>
</tr>
<tr>
<td>PP01.42</td>
<td>CDKN2A, 22q, and BAP1 in Malignant Pleural Mesothelioma</td>
<td>Nhien Dao, Brigham and Women's Hospital, United States</td>
<td></td>
</tr>
</tbody>
</table>
**POSTER LISTINGS**

**Track: Epidemiology**

**PP02.01:** Trends in Mesothelioma Deaths Using Four Different Data Repositories in South Africa
Michel Muteba, University of the Witwatersrand, South Africa

**PP02.02:** The French National Mesothelioma Surveillance Program: Estimates of the National Mesothelioma Incidence - Period 1998-2016
Anabelle Gilg Soit Ilg, Sante Publique France, France

**PP02.03:** Three Asbestos Ores, Three Epidemics, Many Questions
Jim teWaterNaude, Asbestos Relief Trust, South Africa

**PP02.04:** Predicting Mesothelioma Incidence in a Crocidolite Asbestos-Exposed Cohort: The MINKS Study Revisited
Jim teWaterNaude, Asbestos Relief Trust, South Africa

**PP02.05:** Prospective Registry Database of Patients with Malignant Mesothelioma in Japan
Seiki Hasegawa, Hyogo College of Medicine, Japan

**PP02.06:** A Case Series with Unusual Exposures
John Oudyk, Occupational Health Clinics for Ontario Workers, Canada

**PP02.07:** New Approaches to Investigating Malignant Mesothelioma Associated with Naturally Occurring Asbestos Exposures
Francine Baumann, University of New Caledonia, New Caledonia

**PP02.08:** Asbestos Consumption, Eternit and Pleural Mesothelioma in Norway and Denmark: Similar Populations, Different Stories
Oluf Dimitri Røe, Norwegian University of Science and Technology, Norway

**PP02.09:** Criteria and Prognostic Factors among Sarcomatoid Malignant Pleural Mesothelioma Patients: NCI Experience
Hala Aziz Shokralla, National Cancer Institute, Egypt

**PP02.10:** Evaluating Impact of Mesothelioma Underascertainment
Leonid Kopylev, United States Environmental Protection Agency, United States

**PP02.11:** Epidemiological Differences in Mesothelioma Patients with Environmental Asbestos Exposure in Rural Area
Selma Metintas, Eskisehir Osmangazi University, Turkey

**Track: Imaging**

**PP03.01:** Relationship of New Staging System with Survival in Malignant Pleural Mesothelioma Patients
Guntulu Ak, Eskisehir Osmangazi University, Turkey

**PP03.02:** Prospective Analysis of the Diagnostic Yield of MRI after Talc Pleurodesis in Malignant Pleural Mesothelioma
Alessia Stanzi, S. Croce e Carle General Hospital, Italy

**PP03.03:** Geometric Considerations for Measurement of the Diaphragm: Implications for Mesothelioma Thickness Measurements
Christopher Straus, University of Chicago, United States

**PP03.04:** Interobserver Variability of Quantitative Assessment using MR in Malignant Pleural Mesothelioma
Ritu Gill, Beth Israel Deaconess Medical Center, United States
**Track: Medical Oncology**

**PP04.01:** Antiproliferative Effect of a Novel 13-(Di)arylalkyl Berberine in Malignant Mesothelioma Cells
Carme Plasencia, AROMICS, Spain

**PP04.02:** Inhibition of the HGF/C-Met for Mesothelioma with an Intra-Pleural Injection of the NK4 Gene-Expressing Adenoviral Vectors
Yuji Tada, Chiba University, Japan

**PP04.03:** The Presence of Immune Cells and Immune Checkpoints as Therapeutic Targets in Mesothelioma Effusions
Elly Marcq, University of Antwerp, Belgium

**PP04.04:** Maintenance Gemcitabine in Malignant Mesothelioma: A Randomized Phase II Study, NVALT19. Trial in Progress
Cornedine Jannette De Gooijer, The Netherlands Cancer Institute, Netherlands

**PP04.05:** Phase II LUME-Meso Study of First-Line Nintedanib + Chemo in Malignant Pleural Mesothelioma: Additional Efficacy Analyses
Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, United Kingdom

**PP04.06:** New Prognostic Markers in Malignant Pleural Mesothelioma
Sara Ricciardi, University of Pisa, Italy

**PP04.07:** Real-World Experience with Checkpoint Inhibition and PD-L1 Expression in Patients with Malignant Pleural Mesotheliomas
Wei-Chu Lai, Memorial Sloan Kettering Cancer Center, United States

**PP04.08:** Malignant Pleural Mesothelioma: Brain Metastases and Immunotherapy
Ina Nordman, Calvary Mater Newcastle, Australia

**PP04.09:** Phase I/II Clinical Trial to Assess Safety and Efficacy of HVJ-E in Chemotherapy-Resistant Pleural Mesothelioma Patients
Chunman Lee, Osaka University, Japan

**PP04.10:** Effects of Tumor Burden Reduction on Survival in Epithelioid Pleural Mesothelioma
Aaron Mansfield, Mayo Clinic, United States

**PP04.11:** Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma: Phase II Biomarker Data from the LUME-Meso Study
Federica Grosso, SS Antonio e Biagio Hospital, Italy

**PP04.12:** Clinical Characteristics of Malignant Pleural Mesothelioma in the Early Stage
Yuichi Koda, Hyogo College of Medicine, Japan

**PP04.13:** Outcomes of Mesothelioma Patients on CCTG IND.226: A Phase Ib of Durvalumab (D) +/- Tremelimumab (T) +/- Platinum-Doublets
Scott Laurie, The Ottawa Hospital, Canada

**PP04.14:** Outcomes of Nonepithelioid Pleural Mesothelioma in Recent Trials
Abdullah Nasser, The Ottawa Hospital, Canada

**PP04.15:** Tracking the Chemotherapy Resistance of Malignant Pleural Mesothelioma
Kathrin Oehl, University Hospital Zürich, Switzerland

**PP04.16:** MesoBreath 4: Designing the External Validation of a Breath Test for the Early Detection of Malignant Pleural Mesothelioma
Kevin Lamote, University of Antwerp, Belgium

**PP04.17:** Time to Treatment Initiation and Outcomes in Malignant Pleural Mesothelioma: An NCDB Review
Christopher Wee, Cleveland Clinic Foundation, United States

**PP04.18:** MVA-5T4 (TroVax) Vaccine and Combination Chemotherapy in MPM: Results of a Phase II Trial and Immuno-Profiling
Zsuzsanna Tabi, Cardiff University, United Kingdom

**PP04.19:** The Factors of Better Prognosis for Mesothelioma
Takumi Kishimoto, Okayama Rosai Hospital, Japan

**PP04.20:** Malignant Pleural Mesothelioma (MPM) in Egypt: Is It Different?
Fatma Aou El-Kasem, Medical Oncology National Cancer Institute, Egypt

**PP04.21:** Zoledronic Acid in the Management of Mesothelioma: A Feasibility Trial (Zol-A Trial)
Duneesha De Fonseka, University of Bristol, United Kingdom

**PP04.22:** CRP/Albumin Ratio as a Prognostic Marker in Patients with Malignant Pleural Mesothelioma Receiving Active Treatment
Duneesha De Fonseka, University of Bristol, United Kingdom
**POSTER LISTINGS**

**Track: Nursing**

**PP05.01:** Our Research Priorities in Malignant Mesothelioma: Replicating the James Lind Alliance PSP Project in a Small Group Setting
Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom

**Track: Pathology**

**PP06.01:** Glut1 in the Role of Peritoneal Malignant Mesothelioma Diagnosis and Differential Diagnosis
Gao Zhibin, Yuyao People’s Hospital, China

**PP06.02:** Impact of Calretinin Immunohistochemistry and the iMig Guidelines in the Malignant Mesothelioma Diagnosis
Vasiliki Panou, Aalborg University Hospital, Denmark

**Track: Radiation Oncology**

**PP07.01:** The Abscopal Effect in Malignant Mesothelioma: Report on a Case Series
Kenneth O’Byrne, Queensland University of Technology, Australia

**Track: Surgery**

**PP08.01:** Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Malignant Mesothelioma Patients?
Olivia Lauk, University Hospital Zürich, Switzerland

**PP08.02:** Adding Bevacizumab to Standard Induction Chemotherapy for Pleural Malignant Mesothelioma Raises the Risk for Postoperative Bleeding?
Olivia Lauk, University Hospital Zürich, Switzerland

**PP08.03:** Is Extended Pleurectomy/Decortication Superior to Pleurectomy/Decortication for Malignant Pleural Malignant Mesothelioma Patients?
Olivia Lauk, University Hospital Zürich, Switzerland

**PP08.04:** Does Neo-Adjuvant Chemotherapy Affect the Outcomes of Extended Pleurectomy Decortication?
Alan Dawson, Glenfield Hospital, United Kingdom

**PP08.05:** Searching for MARS-2: A United Kingdom Cancer Network’s Specialist Mesothelioma MDT Screening Experience
Shereen Ajab, Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom

**Track: Symptom Control / Palliative Care**

**PP09.01:** Malignant Pleural Mesothelioma among Young People in Central Region of Uganda (Developing Nations Award Winner)
Nehemiya Igulu, Uganda Cancer Institute/Makerere University, Uganda

**Track: Patient Advocacy**

**PP10.01:** Zoledronic Acid in the Management of Mesothelioma: A Feasibility Trial (Zol-A Trial) Qualitative Sub-Study
Duneesha De Fonseka, University of Bristol, United Kingdom

**PP10.02:** Further Update: Impact of BAP1 Mutation on Mesothelioma Risk and Implications for Mesothelioma Litigation
Steven Kazan, Kazan McClain Satterley & Greenwood, United States
INFORMATION FOR INVITED SPEAKERS AND ABSTRACT PRESENTERS

Oral Presenters
Oral Presenters are required to prepare a PowerPoint Presentation for their 10 minute (8 min + 2 min questions and answer period) oral presentation (max. 10 slides not including title, author and disclosure slides). Please make sure that you stick to your allocated time. The session chairs will cut you off after your allocated 10 minutes time slot!

Speaker Ready Room
The Prince Edward Island Room – Level 4 at the Westin Ottawa Hotel is the designated Speaker Ready Room. All presenters are required to submit and/or preview their slides at least 2 hours prior to their scheduled presentation to ensure compatibility with the conference AV equipment.

Computers are available to upload and preview presentations. Speakers are required to report to the Speaker Ready Room at least 2 hours prior to their scheduled presentations. Changes can be made until 90 minutes prior to your presentation. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Ready Room as no file submissions are accepted in the Session Rooms.

Opening Hours
Wednesday, May 2  16:30 – 18:30
Thursday, May 3  07:30 – 16:00
Friday, May 4  07:30 – 16:00
Saturday, May 5  07:30 – 14:00

Poster Setup Time
Thursday, May 3, 2018, 08:00–11:00

Poster Take Down Time
Saturday, May 5, 2018, 14:00–17:00; any posters not removed by 17:00 will be discarded

Poster Hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Setup Hours:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, May 3, 2018</td>
<td>10:15 – 18:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Viewing with Coffee:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, May 3, 2018</td>
<td>10:15 – 11:00 &amp; 15:15 – 16:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Mixer with Poster Discussions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, May 3, 2018</td>
<td>17:30 – 18:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Setup Hours:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, May 4, 2018</td>
<td>10:15 – 18:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Viewing with Coffee:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, May 4, 2018</td>
<td>10:15 – 11:00 &amp; 15:15 – 16:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Mixer with Poster Discussions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, May 4, 2018</td>
<td>17:30 – 18:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Setup Hours:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, May 5, 2018</td>
<td>10:15 – 14:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>Poster Viewing with Coffee:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, May 5, 2018</td>
<td>10:15 – 11:00</td>
</tr>
</tbody>
</table>

Poster Presenters
All poster presentations/boards are located in Exhibit Hall (Confederation II/III – Level 4) at the Westin Ottawa Hotel. A sign identifies each poster board with the assigned poster number and the presenter’s name. The poster board number corresponds with the pre-assigned Final Presentation Number provided in your confirmation letter and used in the abstract book. The size of the poster board and therefore the maximum poster size is: A0 – 33.1 in (w) x 46.8 in (h) – portrait format. Velcro dots will be available onsite.

Presenters are required to stand by their poster during BOTH Poster Mixer with Poster Discussion Sessions (Thursday, May 3 & Friday, May 4 – 17:30–18:30) to answer questions from conference delegates. Please note that Poster Presenters will not be asked to prepare a PowerPoint Presentation.
Leigh Day  Asbestos Disease Lawyers

We help sufferers all over the UK and abroad

- Our team has a formidable reputation in asbestos litigation as a consequence of representing victims for over 30 years in the UK and abroad
- Our clients keep 100% of their compensation
- Our team has achieved the highest compensation awards for pain, suffering and care for mesothelioma victims
- We visit clients at home, hospital or wherever they choose
- We work closely with asbestos disease charities. One of our lawyers has raised over £60,000 and paid it to hospitals to help fund research into a cure for mesothelioma
- We deal with cases quickly and aim to obtain compensation for our clients within 3-6 months

Harminder Bains  Partner  
Daniel Easton  Partner

London: 0207 650 1200 | Manchester: 0161 393 3530 | Liverpool: 0151 305 2760  
Chesterfield: 0124 638 6388 | Birmingham: 0121 728 5909

www.leighday.co.uk/injury-and-illness
CONFERENCE INFORMATION

Conference Venue

The Westin Ottawa Hotel
11 Colonel By Drive, K1N 9H4
Ottawa, ON, Canada
www.thewestinottawa.com

All iMig 2018 Conference Session Rooms as well as Exhibits, Posters and Registration are located in the Westin Ottawa Hotel – Level 4 which is the same building as the delegate guest rooms.

1 Nunavut
Registration (Wednesday, May 2 & Thursday, May 3)

2 Newfoundland
Registration (Friday, May 4 & Saturday, May 5)

3 Confederation I
Plenary Hall

4 Confederation II/III
Exhibits & Posters, Lunch & Coffee Breaks

5 Provinces I
Session Room

6 Provinces II
Session Room

7 Les Saisons (Level 3)
Session Room

8 Prince Edward Island
Speaker Ready Room
Raising awareness about the link between mesothelioma and asbestos
Supporting people affected by mesothelioma
Raising funds for mesothelioma training programs
Developing a national network of expertise in diagnosis and treatment

A registered charity founded by people personally affected by mesothelioma.
www.cmfonline.org

SAVE THE DATE

International Symposium on Malignant Mesothelioma 2019

March 25 - 26, 2019
National Institutes of Health
Bethesda, Maryland
United States

In collaboration with the National Cancer Institute

curemeso.org/sym19
GENERAL INFORMATION FROM A - Z

Abstract Book
All accepted and confirmed abstracts are available on the Conference website at www.iMig2018.org

Badges
Your personalized badge is your admission card to the conference. For organizational and security reasons, badges must be worn in the conference venue at all times.

Cameras and Cell Phones
No cameras or video cameras are allowed in any event during iMig 2018. As a courtesy to fellow delegates, please turn off cell phones during scientific sessions.

Certificate of Attendance
To complete the session evaluation and obtain a certificate for your attendance at iMig 2018, please use the online evaluation system at www.iMig2018.org

Charging Stations
Charging Stations will be available in the Exhibit Hall (Confederation II/III - Level 4) to allow you to take a break while powering your mobile devices.

Delegate Help Desk
Supported by

If you require assistance or any information regarding the Conference as well as the city of Ottawa, see the staff at the Delegate Help Desk located next to the Conference Registration Area.

Exhibition
The Exhibition is located in Confederation II/III - Level 4 at the Westin Ottawa Hotel. Please find a floor plan of the exhibition and a detailed list of all exhibitors on page 36-38.

Exhibition Opening Hours:
Wednesday, May 2 18:30 – 21:30
(Welcome Networking Reception)
Thursday, May 3 10:15 – 18:30
Friday, May 4 10:15 – 18:30
Saturday, May 5 10:15 – 14:00

Lost and Found
Lost and Found items should be returned/claimed at the Conference Registration Area
Room Nunavut May 2nd & 3rd
Newfoundland May 4th & 5th

Notepads
Supported by
Boehringer Ingelheim
Notepads will be available in the registration area for all delegates.

Onsite Mobile Application
Supported by
Bayer
Plan your personalized iMig 2018 Conference schedule. Browse sessions by track, date, and time. The mobile application includes all abstracts submitted and accepted for the iMig 2018 Conference. Available for iPhone, iPad, Android. Download the app from www.iMig2018.org

Poster Session
Supported by
Kazan, McClain, Satterley & Greenwood

Thursday, May 3, 2018
Poster Display Hours: 10:15 – 18:30
Poster Viewing with Coffee: 10:15 – 11:00 & 15:15 – 16:00
Poster Mixer with Poster Discussions: 17:30 – 18:30

Friday, May 4, 2018
Poster Display Hours: 10:15 – 18:30
Poster Viewing with Coffee: 10:15 – 11:00 & 15:15 – 16:00
Poster Mixer with Poster Discussions: 17:30 – 18:30

Saturday, May 5, 2018
Poster Display Hours: 10:15 – 14:00
Poster Viewing with Coffee: 10:15 – 11:00
Poster Viewing with Coffee & Lunches
Poster Viewing with Coffee as well as buffet lunches will be provided for registered delegates in the Exhibit Hall (Confederation II/III - Level 4) throughout the Conference.

Thursday, May 3, 2018
Poster Viewing with Coffee 10:15 – 11:00
Supported by

Lunch 12:30 – 13:45
Poster Viewing with Coffee 15:15 – 16:00
Supported by

MotleyRice

Friday, May 4, 2018
Poster Viewing with Coffee 10:15 – 11:00
Supported by

Provincial Building & Construction

Lunch 12:30 – 13:45
Poster Viewing with Coffee 15:15 – 16:00
Supported by

Saturday, May 5, 2018
Poster Viewing with Coffee 10:15 – 11:00

Public Transportation
By Public Transit
There are two city bus systems in Ottawa. OC Transpo operates in the Ontario side of the Ottawa River and the Société de Transport de l'Outaouais which operates on the Quebec side. You can transfer between these systems along Rideau and Wellington Streets in Ottawa and around the Place d'accueil on Maisonneuve Boulevard in Gatineau. Both agencies offer convenient trip planning tools on their websites.

OC Transpo: www.octranspo.com

By Bicycle
Ottawa has a broad range of cycling experiences for the recreational rider to the serious rider. The recreational pathway network has more than 170 km of pathways people can ride on free of traffic, and along some of the most interesting attractions in Ottawa. The loop of Gatineau Park is a more challenging route for experienced cyclists.

By Taxi
The two main taxi companies in downtown Ottawa are Blue Line Taxi and Capital Taxi.

By Foot
Many attractions in Ottawa can be reached by foot. Many of the city's top attractions include Parliament Hill, Rideau Canal, one of Ottawa's many National Museums, or the Byward Market Neighbourhood.

Registration Counter Hours
iMig 2018 Registration is located in room Nunavut - Level 4 (Wednesday & Thursday) and Newfoundland - Level 4 (Friday & Saturday) at the Westin Ottawa Hotel.
Wednesday, May 2 16:00 – 20:00
Thursday, May 3 07:30 – 17:00
Friday, May 4 07:30 – 17:00
Saturday, May 5 07:30 – 14:00

Smoking
Smoking is prohibited in all areas of the Westin Ottawa Hotel.

Speaker Ready Room
Room Prince Edward Island - Level 4 is the designated Speaker Ready Room. All presenters are required to submit and/or preview their slides at least 2 hours prior to their scheduled presentation to ensure compatibility with the Conference audio visual equipment.

Staff and Volunteers
Volunteers are happy to assist with any questions delegates may have regarding the Conference or Ottawa, Canada. Delegates can easily locate them by their staff/volunteer shirts.

Wireless Internet
Wireless Internet is available throughout the Westin Ottawa Hotel.

Disclaimer
The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes of the Program or any loss that may occur as a result of changes of the Program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
COMMITTED TO RESEARCH

At Kazan Law we go as far as possible within the limits of the legal system to redress the wrong done to each of our clients. But our commitment doesn’t end there. Every day we see the destruction that is done to families that have been touched by mesothelioma, and we strive to help you find a cure.

Our firm took a significant step towards this goal in 1994, when the Kazan McClain Partners’ Foundation, Inc., was formed. Over the years we and our clients have disbursed over $6 million in support of mesothelioma research at esteemed learning institutions.

iMig Young Investigator Awards

Kazan Law congratulates the iMig 2018 Young Investigator Award recipients. We are proud to have first proposed this important recognition of the junior scientists joining our mesothelioma community, and are honored to have funded it since it began in 2008.

Additional $100,000 to Support iMig Attendees

To further our support of iMig, the Kazan McClain Partners’ Foundation has set aside an additional $100,000 to fund micro research grants for iMig 2018 attendees, an offer we have had the privilege of extending since 2014. To apply, please send a brief email to skazan@kazanlaw.com explaining how much money you need, what you will spend it on, and what publishable goals you hope to accomplish.

For more information, visit us at www.kazanlaw.com/iMig-2018
AWARDS

iMig Wagner Medal
The iMig Wagner Medal will be awarded during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

In honor of the contributions of Dr. J. Christopher Wagner to the understanding of mesothelioma, its cause, and goals for prevention, the International Mesothelioma Interest Group presents the Wagner Medal every two years to an individual who has made major original contributions to the understanding of mesothelioma, either in basic or applied research. The Wagner Medal is the highest honor presented by the International Mesothelioma Interest Group to a leader in the field.

2002 Marie-Claude Jaurand, PhD, France
2004 Bruce Robinson, MD, Australia
2006 Harvey Pass, MD, USA
2008 Brooke Mossman, PhD, USA
2010 Steven Albelda, MD, USA
2012 Joseph R. Testa, PhD, USA
2014 Raffit Hassan, MD, USA
2016 Courtney Broaddus, MD, USA

iMig Research Award
The iMig Research Award will be awarded during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

The iMig Research Award will be awarded every two years to recognize the potential significance and impact on the field of novel mesothelioma research (basic, translational, or clinical) that has been published or presented since the prior International Conference of the International Mesothelioma Interest Group. Research to be presented during the current Conference would make an investigator eligible for nomination for the iMig Research Award.

iMig Service Award
The iMig Service Award will be awarded during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

The iMig Service Award may be awarded every two years to an individual who has made significant and sustained contributions of service to the mission of the International Mesothelioma Interest Group and the mesothelioma community.

Best Investigator Award
The Best Investigator Award will be awarded during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

Best Poster Award
The Best Poster Award will be awarded during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

Young Investigator Awards
Supported by

Young Investigator Award Recipients will receive their awards during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

Bethany Taylor, United Kingdom
MS07.04: Receiving a Diagnosis of MESOthelioma (RADIO Meso): Improving the Patient Experience

David Chapel, United States
MS09.06: A Comprehensive Prognostic Model for Malignant Peritoneal Mesothelioma: Interim Analysis of an International Collaboration

Elisabetta Casalone, Italy
MS10.01: Serum miRNA Profiling of Malignant Pleural Mesothelioma and Early Diagnosis: A Massive Parallel Sequencing Approach

Rachael Zemek, Australia
MS13.06: Rational Therapeutic Modulation of the Tumor Microenvironment Sensitizes Cancers to Immune Checkpoint Blockade

Jo Raskin, Belgium
PL05.02: EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM

Developing Nations Travel Grant
The Developing Nations Travel Grant will be awarded during the Presidential Closing Address on Saturday, May 5, 15:30 - 16:00.

Nehemiya Igulu, Uganda
PP09.01: Malignant Pleural Mesothelioma in Young People
INDUSTRY SUPPORTED SYMPOSIA
Thursday, May 3 | 12:45 - 13:45

Systemic Therapy of Malignant Pleural Mesothelioma: First-line and Beyond
Room: Confederation I – Level 4

Chair: Dr. Quincy Chu, Cross Cancer Institute, Edmonton, AB

Speakers:
Dr. Paul Wheatley-Price, The Ottawa Hospital, Ottawa, ON
Dr. Penelope Bradbury, Princess Margaret Cancer Centre, Toronto, ON

12:45 - 12:50
Introduction and Audience Poll
Dr. Quincy Chu

12:50 – 13:20
Debate: “There are NO True Second-Line Systemic Treatment Options for Malignant Pleural Mesothelioma”
PRO: Dr. Paul Wheatley-Price
CON: Dr. Penelope Bradbury

13:20 – 13:25
Final Audience Poll
Dr. Quincy Chu

13:25 – 13:40
What are the First-Line Systemic Treatment Options for Malignant Pleural Mesothelioma?
Dr. Penelope Bradbury

1:40 - 1:45 PM
Discussion / Questions
Dr. Paul Wheatley-Price
Dr. Penelope Bradbury
Dr. Quincy Chu

Supported by

Asbestos.com®
Brought to you by The Mesothelioma Center

WE CONNECT PATIENTS & FAMILIES WITH:

- Doctors & Treatment Facilities
- Support Groups & Informational Resources
- Clinical Trial Locations & Enrollment
- Health Insurance & Travel Support
- Financial & Legal Assistance
- VA & Social Security Benefits
EXHIBITION INFORMATION

Exhibition Location and Hours
The Exhibition is located in Confederation II/III - Level 4 at the Westin Ottawa Hotel.

Exhibition Opening Hours
Wednesday, May 2 18:30 – 21:30
(Welcome Networking Reception)
Thursday, May 3 10:15 – 18:30
Friday, May 4 10:15 – 18:30
Saturday, May 5 10:15 – 14:00

Exhibition Highlights
Wednesday, May 2 18:30 – 21:30
(Welcome Networking Reception)
The iMig 2018 Exhibition will open with the Welcome Networking Reception, allowing you the opportunity to mix and mingle with exhibitors, colleagues and friends.

Supported by

Exhibitor Listing - Alphabetical

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asbestos Disease Awareness</td>
<td>7</td>
</tr>
<tr>
<td>Organization (ADAO)</td>
<td></td>
</tr>
<tr>
<td>Canadian Labour Congress (CLC)</td>
<td>14</td>
</tr>
<tr>
<td>Canadian Mesothelioma Foundation</td>
<td>2</td>
</tr>
<tr>
<td>Canadian Society for Asbestos Victims (CanSAV)</td>
<td>8</td>
</tr>
<tr>
<td>DLD Diagnostika GmbH</td>
<td>10</td>
</tr>
<tr>
<td>Kazan, McClain, Satterley &amp; Greenwood</td>
<td>9</td>
</tr>
<tr>
<td>Leigh Day</td>
<td>1</td>
</tr>
<tr>
<td>Lung Cancer Canada</td>
<td>3</td>
</tr>
<tr>
<td>Mesobank Mick Knighton Mesothelioma</td>
<td>15</td>
</tr>
<tr>
<td>Tissue Bank</td>
<td></td>
</tr>
<tr>
<td>Mesothelioma Applied Research</td>
<td>18</td>
</tr>
<tr>
<td>Foundation (MARF)</td>
<td></td>
</tr>
<tr>
<td>Motley Rice LLC</td>
<td>5</td>
</tr>
<tr>
<td>Novocure</td>
<td>6</td>
</tr>
<tr>
<td>Occupational Health Clinics for Ontario Workers</td>
<td>13</td>
</tr>
<tr>
<td>The Mesothelioma Center at Asbestos.com</td>
<td>16</td>
</tr>
<tr>
<td>Unifor</td>
<td>4</td>
</tr>
</tbody>
</table>

Diagram with booth numbers and food and charging station locations.
EXHIBITION BIOGRAPHIES

Asbestos Disease Awareness Organization (ADAO) | Booth 7
www.adao.us
An independent nonprofit, was founded by the Reinstein and Larkin families in 2004. ADAO remains dedicated to raising public awareness about the dangers of asbestos exposure, advocating for an asbestos ban, and protecting asbestos victims’ civil rights through our education, advocacy, and community initiatives.

Canadian Labour Congress (CLC) | Booth 14
www.canadianlabour.ca
The Canadian Labour Congress brings together national and international unions, provincial and territorial federations of labour and community-based labour councils to represent 3.3 million workers. In 2016, after years of advocacy for safer, healthier workplaces, the CLC won a ban on the import, export and use of asbestos in Canada.

Canadian Mesothelioma Foundation | Booth 2
www.cmfonline.org
The Canadian Mesothelioma Foundation, a registered charity, was founded by people personally affected by mesothelioma. We raise awareness about the link between mesothelioma and asbestos, and support those affected by mesothelioma. We also provide grants to mesothelioma programs and are developing a health network across Canada.

Canadian Society for Asbestos Victims (CanSAV) | Booth 8
www.cansav.ca
The Canadian Society for Asbestos Victims (CanSAV) is a registered non-profit organization dedicated to providing support, advocacy, facilitation, and education to serve Canadians families impacted by asbestos-related diseases. As these diseases are life-altering, occupational diseases, CanSAV recognizes the need to accelerate access to health and compensation services through shared, community resources. We encourage impacted families to seek entitlements within existing health and compensation systems and facilitate a toll free service for support.

DLD Diagnostika GmbH | Booth 10
www.ldd-diagnostika.de
DLD developed a new ELISA test for the early detection of human calretinin being increased in patient with malignant mesothelioma. The novel assay is highly specific and sensitive using human serum and plasma. The test is robust, easy to perform and validated in large case-control studies.

Kazan, McClain, Satterley & Greenwood | Booth 9
www.kazanlaw.com
Since 1974 Kazan Law has been deeply committed to advocating for mesothelioma patients and their families, getting them the maximum compensation American law allows, while providing millions to support medical research and the international ban asbestos movement. We proudly contribute our exhibitor’s table to two wonderful British victims’ groups.

Leigh Day | Booth 1
www.leighday.co.uk
Leigh Day is a UK law firm with offices in London & other major cities. We have specialised in asbestos cases for over 25 years across the globe. Our cases have set precedents and we have won the highest amounts of compensation for our clients in these cases.

Lung Cancer Canada | Booth 3
www.lungcancercanada.ca
Lung Cancer Canada is Canada’s only national charitable organization focused solely on lung cancer. Our mission is to increase awareness about lung cancer, support patients living with lung cancer and the individuals who care for them and provide educational resources to lung cancer patients, their families and health care professionals.
EXHIBITION BIOGRAPHIES

Mesobank Mick Knighton Mesothelioma Tissue Bank | Booth 15 www.mesobank.com
Mesobank is the UK’s largest unique collection of high-quality tissue, blood samples and data from mesothelioma patients. Novel cell lines, DNA and a TMA of >800 patients are also available. Mesobank is dedicated to the study of mesothelioma by providing samples for research.

Mesothelioma Applied Research Foundation (MARF) | Booth 18 www.curemeso.org
The Mesothelioma Applied Research Foundation is an independent nonprofit organization dedicated to ending mesothelioma and the suffering caused by this cancer, by funding peer-reviewed research; providing education and support for patients and their families; and by advocating for federal funding of mesothelioma research. Founded in 1999, the organization has, to date, awarded over $10 million to research.

Motley Rice LLC | Booth 5 www.motleyrice.com
One of the largest U.S. plaintiffs’ firms, Motley Rice LLC is U.S. legal counsel in asbestos recovery efforts for workers’ compensation boards and individuals throughout Canada. The firm pioneered asbestos lawsuits and negotiated the landmark Tobacco Master Settlement, and today handles complex litigation in numerous areas, including toxic exposures and occupational diseases, anti-terrorism, medical drugs and devices, aviation/transportation, and catastrophic injury.

Novocure | Booth 6 www.novocure.com
Novocure is a global oncology company developing a proprietary therapy called Tumor Treating Fields for the treatment of solid tumor cancers. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

Occupational Health Clinics for Ontario Workers | Booth 13 www.ohcow.on.ca
Occupational Health Clinics for Ontario Workers (OHOW) is dedicated to the identification and prevention of work-related illnesses and injuries. The first OHOW Clinic opened in Hamilton in 1989. There are now seven Clinics in Ontario funded by the Ministry of Labour (MOL). Each Clinic has an Executive Director and is staffed by a dedicated inter-disciplinary team of occupational specialists.

The Mesothelioma Center at Asbestos.com | Booth 16 www.asbestos.com
Since its inception in 2006, Asbestos.com has served as an advocacy center, providing hope and delivering quality resources to patients and loved ones coping with mesothelioma. We seek to educate everyone about asbestos and mesothelioma with free access to information, services and support to overcome this disease.

Unifor | Booth 4 www.unifor.org
Unifor is Canada’s largest union in the private sector, representing 315,000 workers in every major area of the economy. The union advocates for all working people and their rights, fights for equality and social justice in Canada and abroad, and strives to create progressive change for a better future.
it takes knowledge + ACTION to make change happen

CAUSES, NOT JUST CASES

Advocating awareness and protections for asbestos victims
Serving as U.S. legal counsel for workers’ compensation boards and people throughout Canada in asbestos recovery efforts in the U.S.

www.motleyrice.com
+1.800.768.4026
28 Bridgeside Blvd., Mt. Pleasant, SC 29464 USA

Contact Anne McGinness Kearse.
Our attorneys are not licensed to practice law in Canada.
The International Association of Heat and Frost Insulators and Allied Workers

is proud to support
the
International Mesothelioma Interest Group
iMig 2018 Conference

... "Working to Understand, Prevent and Cure Mesothelioma"

JAMES P. MC COURT  GREGORY T. REVARD
General President  General Secretary-Treasurer

INTERNATIONAL VICE PRESIDENTS

Doug Gamble  Terry Larkin  Mark Selby  Vince Engel  Pat Barron
Timothy Keane  Paul Faulkner  Don Stanley  Leo Damaris  Bob Reap

INTERNATIONAL REPRESENTATIVES

Rob Hall  John Conroy  Tom Haun

Affiliated with the AFL-CIO, Building and Construction Trades Department, Metal Trades Department and Canadian Labour Congress
DEFENDING SCIENCE IN THE AGE OF FAKE NEWS.

The Professional Institute of the Public Service of Canada

pipsc.ca/science
When a community is built from the ground up, there is no labour force on the planet, better skilled to get the job done right the first time. LiUNA members and retirees made a commitment to their careers, which means a commitment to our communities. A commitment to build the BEST schools, airports, hospitals, office buildings, tunnels, power plants, roads, bridges, low rise and high rise housing in the country. When the work is done, LiUNA members and retirees continue to live, play and grow in their communities, with the guarantee of a pension that is also....simply the BEST!

Over 100,000 members and retirees across Ontario, LiUNA is committed to building communities throughout the Province. While our affiliates specialize in representing construction workers, we also represent many other industries including manufacturing, health care, custodial services, convention and show exhibits.
Like You, 
We Are Proud Members of the 
International Mesothelioma Community

As a clinician or research scientist, you are working to understand, cure and prevent mesothelioma. Like you, Kazan Law is deeply committed to advocating for mesothelioma patients and their families. Since 1974, we have helped victims of mesothelioma and asbestos-related cancers get the maximum compensation the law allows.

Our firm strives to make a broader contribution to the mesothelioma community through support which includes:

• iMig – It has been our privilege to be a major financial supporter since 2006.
• Mesothelioma research – The Kazan McClain Partners’ Foundation has funded over $6 million for mesothelioma research at leading medical facilities.
• Ban Asbestos – Our firm and its Foundation has been the major financial supporter of the International Ban Asbestos Secretariat, which coordinates the worldwide asbestos ban campaigns, for over 20 years.
• Mesothelioma Circle – Our firm sponsors a website devoted to providing patients and their families with resources to help them make important decisions about health, financial and legal issues. It also provides a unique clinical trials navigation service.

We hope to be of service to you as you provide compassionate and personalized care to your patients. We invite you and your patients to look to us as a potential path to justice, financial support, and information during a painful and difficult time in their lives.